Episode Details
Back to Episodes
ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors
Published 1 year, 3 months ago
Description
He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2 program.